BioVie appoints Amy Chappell and Kameel Farag to Board of Directors

BIOVIE INC.

Board expanded from 4 to 6 members; appointments effective July 17, 2025.
Dr. Chappell: 25 years at Eli Lilly, led CNS drug development including Cymbalta; former CMO of Eliem Therapeutics.
Mr. Farag: former CFO of Aspen Neuroscience (raised $150M+), SVP Finance at Ionis, Regional CFO at Amgen.
BioVie advancing bezisterim Phase 2 trials for early Parkinson's (SUNRISE-PD) and long COVID (ADDRESS-LC).

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.